TCT 2019

TCT 2019

Transplantation and Cellular Therapy Meetings 2019

Follow us at TCT: #TCTM19

Fred Hutch scientists are presenting new research findings at the Transplantation & Cellular Therapy (TCT) Meetings on February 20-24, 2019. TCT represents the combined annual meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR).

The meeting features the E. Donnall Thomas Lecture, named after the late Nobel laureate who pioneered bone marrow transplantation at Fred Hutch. The lecture recognizes an eminent physician or scientist who has contributed meritoriously to the advancement of knowledge in blood and marrow transplantation.

Highlighted Abstracts and Schedule

Wednesday, February 20

Advances in Graft Engineering for GVHD Reduction
Marie Bleakley, M.D., Ph.D.
Wednesday, February 20, 9:00 a.m.
George R. Brown Convention Center - GRB-Grand Ballroom ABC
 

Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL
Jordan Gauthier, M.D., M.Sc.
Wednesday, February 20, 5:30 p.m.
George R. Brown Convention Center - GRB-Grand Ballroom ABC

In relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients who had previously failed ibrutinib, we observed durable responses after CD19 chimeric antigen receptor-modified T-cell immunotherapy. The combination of CD19 CAR-T cells with ibrutinib might improve response and decrease toxicity.
 

20 Years of Experience with Allogeneic Hematopoietic Cell Transplantation in the Outpatient Setting (Poster)
Noa Granot, M.D.
Wednesday, February 20, 6:45 – 7:45 p.m.
George R. Brown Convention Center - GRB-Exhibit Hall B3

Reduced intensity conditioning with fludarabine and low dose total body irradiation before allogeneic hematopoietic stem cell transplantation (HCT) was developed to treat older or medically infirm patients with advanced hematologic malignancies. Given the regimen’s low toxicity, it lends itself to be an outpatient procedure. Nevertheless, some patients experienced adverse events, leading to hospitalization during the first 100 days after HCT. 
 

Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study (Poster)
Mohamed Sorror, M.D., M.Sc.
Wednesday, February 20, 6:45 – 7:45 p.m.
George R. Brown Convention Center - GRB-Exhibit Hall B3

Older patients with AML often have significant comorbidities and other geriatric health problems, and the effect of these on the probability of receiving HCT is unknown. We designed a prospective, longitudinal, observational study of adult patients with AML dating from first presentation at one of 13 centers. We examined the effects of different variables on the probability to 1) survive long enough to receive HCT and 2) to receive HCT if such survival occurred.

Thursday, February 21

Factors Associated with Toxicity of CD19 CAR-T Cell Immunotherapy
Cameron J. Turtle, MBBS, Ph.D.
Thursday, February 21, 11:00 a.m.
George R. Brown Convention Center - GRB-Grand Ballroom ABC

Friday, February 22

Mortimer M. Bortin Lecture - Treatment of Chronic Graft‐versus‐host Disease—Progress to Date and Challenges Ahead
Paul Martin, M.D.
Friday, February 22, 5:45 p.m.
Hilton Americas Houston - Ballroom of the Americas A

This year marks the 40th anniversary of the first publications focused on chronic GVHD in humans. The 2019 Mortimer Bortin Lecture will briefly review key milestones in defining the clinical manifestations of the disease, its evolution from onset to progressive disability, and the principles of clinical management based largely on the empiric use of glucocorticoids and other immunosuppressive treatments. 

Saturday, February 23

Creation of Personalized Patient Care Plans for HCT Survivors
Scott Baker, M.D., M.S.
Saturday, February 23, 11:30 a.m.
Hilton Americas Houston - Grand Ballroom A
 

Oral Brincidofovir Decreased HHV-6 Viremia in Hematopoietic Cell Transplant Recipients: Results from the Suppress Study (Poster)
Joshua Hill, M.D.
Saturday, February 23, 6:45 – 7:45 p.m.
George R. Brown Convention Center - GRB-Exhibit Hall B3

Human herpesvirus 6B (HHV-6) is detected in plasma in ~40% of allogeneic hematopoietic cell transplant (HCT) recipients and ~75% of cord blood recipients. HHV-6 viremia, particularly at levels >104 copies/mL, is associated with increased risk for HHV-6 encephalitis. Ganciclovir and foscarnet have antiviral activity against HHV-6, but studies of pre-emptive or prophylactic treatment have not been successful in preventing HHV-6 encephalitis. Prophylaxis for HHV-6 has never been studied in a randomized trial. Brincidofovir (BCV, CMX001) has potent in vitro activity against HHV-6 (EC50=0.007 µM), and unlike cidofovir, has good CNS penetration.
 

Whole Blood RNA-Seq Differentiates Hematopoietic Cell Transplant Recipients with Upper Versus Lower Respiratory Tract Rhinovirus Infection (Poster)
Alpana Waghmare, M.D.
Saturday, February 23, 6:45 – 7:45 p.m.
George R. Brown Convention Center - GRB-Exhibit Hall B3

Human rhinovirus (HRV) is the most common virus detected in the respiratory tract following hematopoietic cell transplantation (HCT). Mortality following virologically proven lower respiratory tract infection (LRTI) may be up to 40%. Specific immune processes activated in upper respiratory tract infection (URTI) vs LRTI are not well understood.
 

Quantifying Cytomegalovirus-Specific T Cell Responses Prior to Hospital Discharge Allows Risk Stratification for Late Viral Reactivation after Allogenic Hematopoietic Cell Transplantation (Poster)
Michael Boeckh, M.D., Ph.D.
Saturday, February 23, 6:45 – 7:45 p.m.
George R. Brown Convention Center - GRB-Exhibit Hall B3

Cytomegalovirus (CMV) infection remains a significant complication after allogenic hematopoietic cell transplantation (HCT). In the first three months after HCT, close monitoring of patients associated with prophylactic or preemptive administration of ganciclovir effectively prevents CMV-related complications. However, once patients are discharged from cancer centers around day 100 after HCT their risk of late CMV reactivation remains high. Since virus-specific T cells are capable of controlling CMV replication, we assessed whether their quantification shortly before hospital discharge allows risk-stratification for late CMV reactivation.

Sunday, February 24

CMV Viral Load after Peripheral Blood Stem Cell Transplantation (PBSCT) and Posttransplant High-Dose Cyclophosphamide (PTCy)
Masumi Ueda, M.D., M.A.
Sunday, February 24, 11:00 a.m.
Hilton Americas Houston - Grand Ballroom A

CMV viral load after allogeneic hematopoietic PBSCT is strongly associated with overall and non-relapse mortality. Recent studies suggest graft-versus-host-disease (GVHD) prevention with PTCy reduces GVHD risk through an immunomodulatory mechanism rather than T-cell ablation, which may preserve virus-specific adaptive immune responses. We hypothesized that GVHD prophylaxis using PTCy leads to lower CMV viral load and disease compared to calcineurin-inhibitor (CNI) and methotrexate (MTX) or mycophenolate (MMF) GVHD regimens after PBSCT.

Related Stories

For more information or to arrange an interview, please contact our Media Relations team at 206.667.2210 or email us.